AR079059A1 - ACID ((3S) -3 - (((1 - (((2R) -2-CARBOXI-4- (1-NAFTIL) BUTIL) CYCLOPENTIL) -CARBONYL) AMINO) -2-OXO-2,3,4, 5-TETRAHIDRO-1H-1-BENZAZEPIN-1-IL) ACETICO CRISTALINO, ITS PREPARATION AND USE - Google Patents

ACID ((3S) -3 - (((1 - (((2R) -2-CARBOXI-4- (1-NAFTIL) BUTIL) CYCLOPENTIL) -CARBONYL) AMINO) -2-OXO-2,3,4, 5-TETRAHIDRO-1H-1-BENZAZEPIN-1-IL) ACETICO CRISTALINO, ITS PREPARATION AND USE

Info

Publication number
AR079059A1
AR079059A1 ARP100104251A ARP100104251A AR079059A1 AR 079059 A1 AR079059 A1 AR 079059A1 AR P100104251 A ARP100104251 A AR P100104251A AR P100104251 A ARP100104251 A AR P100104251A AR 079059 A1 AR079059 A1 AR 079059A1
Authority
AR
Argentina
Prior art keywords
benzazepin
oxo
carbonyl
amino
acid
Prior art date
Application number
ARP100104251A
Other languages
Spanish (es)
Inventor
Rheenen Jeroen Van
Dasselaar Eric Eibert Van
Guido Dirk Batema
Jong Paulus Petrus Gerardus De
Touria Elhamdaoui-Achterberg
Nicolaas Buizer
Gerrit Klein
Original Assignee
Abbott Healthcare Products Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Healthcare Products Bv filed Critical Abbott Healthcare Products Bv
Publication of AR079059A1 publication Critical patent/AR079059A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composicion farmacéutica y proceso de preparacion. Reivindicacion 1: Ácido {(3S)-3-[((1-[(2R)-2-carboxi-4-(1-naftil)butil]ciclopentil}-carbonil)amino]-2-oxo-2,3,4,5-tetrahidro-1H-1-benzazepin-1-il)acético cristalino, caracterizado porque es el compuesto de formula (1). Reivindicacion 2: El compuesto de acuerdo con la reivindicacion 1, caracterizado porque tiene un espectro de difraccion de rayos X de polvo que tiene reflejos característicos (expresados en grados del ángulo de difraccion 2 theta) a: 16.32, 17.05, 20.38. Reivindicacion 4: El compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 3, caracterizado porque tiene un espectro infrarrojo registrado en Reflectancia Total Atenuada que tiene bandas de absorcion características a 3426, 3267, 3060, 2936, 2876, 2598, 2456, 1736, 1639, 1597, 1512, 1487, 1459, 1441, 1424, 1391, 1315, 1232, 1191, 1137, 781, 773, 735, 713, 670 cm-1. Reivindicacion 5: El compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 4, caracterizado porque tiene un espectro 13C-NMR en estado solido con desplazamientos característicos (expresados en ppm con relacion a glicina (delta c = 176,03 para la resonancia C=O)) a: 177.0, 176.0, 174.7, 172.2, 169.7, 138.9, 136.4, 133.6, 131.5, 130.2, 127.8, 126.5, 125.3, 124.2, 123.2, 121.9, 55.1, 51.0, 41.9, 40.8, 38.5, 37.1, 28.4, 25.9, 23.1, 21.1 +- 0.1 ppm.Pharmaceutical composition and preparation process. Claim 1: {(3S) -3 - [((1 - [(2R) -2-carboxy-4- (1-naphthyl) butyl] cyclopentyl} -carbonyl) amino] -2-oxo-2,3 acid, Crystalline 4,5-tetrahydro-1H-1-benzazepin-1-yl), characterized in that it is the compound of formula (1). Claim 2: The compound according to claim 1, characterized in that it has a powder X-ray diffraction spectrum having characteristic reflections (expressed in degrees of diffraction angle 2 theta) at: 16.32, 17.05, 20.38. Claim 4: The compound according to any one of claims 1 to 3, characterized in that it has an infrared spectrum recorded in Attenuated Total Reflectance having characteristic absorption bands at 3426, 3267, 3060, 2936, 2876, 2598, 2456, 1736, 1639, 1597, 1512, 1487, 1459, 1441, 1424, 1391, 1315, 1232, 1191, 1137, 781, 773, 735, 713, 670 cm-1. Claim 5: The compound according to any one of claims 1 to 4, characterized in that it has a solid state 13C-NMR spectrum with characteristic shifts (expressed in ppm relative to glycine (delta c = 176.03 for resonance C = O)) a: 177.0, 176.0, 174.7, 172.2, 169.7, 138.9, 136.4, 133.6, 131.5, 130.2, 127.8, 126.5, 125.3, 124.2, 123.2, 121.9, 55.1, 51.0, 41.9, 40.8, 38.5, 37.1, 28.4 , 25.9, 23.1, 21.1 + - 0.1 ppm.

ARP100104251A 2009-12-07 2010-11-18 ACID ((3S) -3 - (((1 - (((2R) -2-CARBOXI-4- (1-NAFTIL) BUTIL) CYCLOPENTIL) -CARBONYL) AMINO) -2-OXO-2,3,4, 5-TETRAHIDRO-1H-1-BENZAZEPIN-1-IL) ACETICO CRISTALINO, ITS PREPARATION AND USE AR079059A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09178226 2009-12-07

Publications (1)

Publication Number Publication Date
AR079059A1 true AR079059A1 (en) 2011-12-21

Family

ID=41682516

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100104251A AR079059A1 (en) 2009-12-07 2010-11-18 ACID ((3S) -3 - (((1 - (((2R) -2-CARBOXI-4- (1-NAFTIL) BUTIL) CYCLOPENTIL) -CARBONYL) AMINO) -2-OXO-2,3,4, 5-TETRAHIDRO-1H-1-BENZAZEPIN-1-IL) ACETICO CRISTALINO, ITS PREPARATION AND USE

Country Status (3)

Country Link
AR (1) AR079059A1 (en)
TW (1) TW201127815A (en)
WO (1) WO2011069944A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19510566A1 (en) 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepine, benzoxazepine and benzothiazepine N-acetic acid derivatives and process for their preparation and medicaments containing these compounds
DE19638020A1 (en) 1996-09-18 1998-03-19 Solvay Pharm Gmbh Gastrointestinal blood flow promoting drugs
WO2005067937A1 (en) 2004-01-12 2005-07-28 Solvay Pharmaceuticals B.V. Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors for prophylaxis and treatment of neurodegenerative disorders
US7232813B2 (en) 2004-01-12 2007-06-19 Solvay Pharmaceuticals B.V. Neutral endopeptidase (NEP) and human soluble endopeptidase (hSEP) inhibitors for prophylaxis and treatment of neuro-degenerative disorders
EP1827448A1 (en) 2004-12-15 2007-09-05 Solvay Pharmaceuticals GmbH Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and hmg coa reductase inhibitors

Also Published As

Publication number Publication date
TW201127815A (en) 2011-08-16
WO2011069944A1 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
WO2012066308A3 (en) Compositions
EP2815768A3 (en) Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
WO2006052968A3 (en) Stabilized ramipril compositions and methods of making
CL2011000867A1 (en) Da, c and ii crystalline forms of (r) -5- [3-chloro-4- (2,3-dihydroxy-propoxy) -benz [z] ylidene] -2- ([z] - propylimino) -3-o - totil-thiazolidin-4-one; pharmaceutical composition; and use in the treatment or prevention of rejection of transplanted organs, autoimmune syndrome, asthma, diabetes, cancer.
EP2499195A4 (en) Oxygen scavengers, compositions comprising the scavengers, and artcles made from the compositions
WO2009156405A8 (en) Novel immunoadjuvant flagellin-based compounds and use thereof
DE602007014411D1 (en) MEDICAL DISPENSING SYSTEM WITH LOCKING RING WITH L-SHAPED NUTS
WO2009003998A3 (en) Antiproliferative compounds based on 5-membered heterocycles
CN102036649A8 (en) Arginine salt and its purposes for treating mouth disease
PL1695709T3 (en) Crystalline form gamma-d of the chlorohydrate of ivabradine, process for its preparation and pharmaceutical compositions containing it
WO2011008823A3 (en) Peptide-mediated non-covalent delivery of active agents across the blood brain barrier
WO2010003992A8 (en) Combination of a c-met antagonist and an aminoheteroaryl compound for the treatment of cancer
EP2376348A4 (en) Package for oxygen-sensitive pharmaceutical products
EA200870422A1 (en) IMPROVED DISTRIBUTION DEVICE
WO2009115084A3 (en) Pyrrolopyrimidine derivatives, and use thereof
AR081324A1 (en) PRODUCTION OF HIGH DENSITY UNIFIED COMPOSITIONS
MX347070B (en) 2-oxo-1-pyrrolidinyl imidazothiadiazole derivatives.
IL208463A (en) 2-heterocyclyl-fused pyrrole compounds, pharmaceutical compositions comprising them and their use in the prophylaxis or treatment of diabetes or obesity
WO2011069037A3 (en) Stabilization and storage of biological pharmaceutical compositions
IL209304A0 (en) Peptides, peptidomimetics and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
NO20084942L (en) Procedure for increasing or affecting the shelf life of agricultural products producing ethylene during transport and / or storage
AR079059A1 (en) ACID ((3S) -3 - (((1 - (((2R) -2-CARBOXI-4- (1-NAFTIL) BUTIL) CYCLOPENTIL) -CARBONYL) AMINO) -2-OXO-2,3,4, 5-TETRAHIDRO-1H-1-BENZAZEPIN-1-IL) ACETICO CRISTALINO, ITS PREPARATION AND USE
IL200069A0 (en) Atorvastatin strontium salts, pharmaceutical composition comprising the same and methods of producing the same
WO2012036523A3 (en) Novel antibiotically active compound and an antibiotic composition comprising the compound
GB0620619D0 (en) Novel compounds

Legal Events

Date Code Title Description
FB Suspension of granting procedure